ATE513560T1 - Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird - Google Patents

Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird

Info

Publication number
ATE513560T1
ATE513560T1 AT03732933T AT03732933T ATE513560T1 AT E513560 T1 ATE513560 T1 AT E513560T1 AT 03732933 T AT03732933 T AT 03732933T AT 03732933 T AT03732933 T AT 03732933T AT E513560 T1 ATE513560 T1 AT E513560T1
Authority
AT
Austria
Prior art keywords
bacterial meningitis
mucosa
induces
antigen
vaccine against
Prior art date
Application number
AT03732933T
Other languages
English (en)
Inventor
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE513560T1 publication Critical patent/ATE513560T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03732933T 2002-05-14 2003-05-14 Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird ATE513560T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38067502P 2002-05-14 2002-05-14
PCT/IB2003/002648 WO2003094960A2 (en) 2002-05-14 2003-05-14 Mucosal combination vaccines for bacterial meningitis

Publications (1)

Publication Number Publication Date
ATE513560T1 true ATE513560T1 (de) 2011-07-15

Family

ID=29420626

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03732933T ATE513560T1 (de) 2002-05-14 2003-05-14 Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird

Country Status (12)

Country Link
US (2) US20060147466A1 (de)
EP (1) EP1506007B1 (de)
JP (2) JP4662537B2 (de)
CN (2) CN1816350B (de)
AT (1) ATE513560T1 (de)
AU (1) AU2003239744B2 (de)
BR (1) BR0310042A (de)
CA (1) CA2485999C (de)
MX (1) MXPA04011248A (de)
NZ (1) NZ536859A (de)
RU (1) RU2378008C2 (de)
WO (1) WO2003094960A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
DE602005025342D1 (de) * 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008101349A1 (en) 2007-02-23 2008-08-28 Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence Recombinant viral vectors for prevention and protection against alphavirus infection
CN101249261B (zh) * 2008-03-18 2010-10-27 中国疾病预防控制中心病毒病预防控制所 一种肾综合征出血热粘膜免疫疫苗及其制备方法
WO2010142017A1 (en) * 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN104383531A (zh) * 2014-11-18 2015-03-04 北京智飞绿竹生物制药有限公司 预防儿童脑膜炎的联合疫苗及其制备方法
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN105031644A (zh) * 2015-06-25 2015-11-11 中国科学院过程工程研究所 一种疫苗佐剂及含该疫苗佐剂的疫苗组合物和疫苗制剂
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
KR20240018698A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
TWI852943B (zh) 2018-09-12 2024-08-21 美商兒童醫療中心公司 肺炎鏈球菌融合蛋白疫苗
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
RU2704452C1 (ru) * 2019-04-22 2019-10-28 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения вакцины гемофильной тип b конъюгированной
EP4034157A1 (de) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria-meningitidis-zusammensetzungen und verfahren dafür
EP4192499A4 (de) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalente pneumokokken-glykokonjugat-impfstoffe, die nachkommende serotyp 24f enthalten
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2002506448A (ja) * 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE69939943D1 (de) * 1998-10-21 2009-01-02 Kitasato Inst Attenuierte Toxine als Adjuvantien
JP2002539273A (ja) * 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
IL150602A0 (en) * 2000-02-15 2003-02-12 Id Biomedical Corp Quebec Proteosome influenza vaccine
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
DK1296715T4 (en) * 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP2004527524A (ja) * 2001-04-05 2004-09-09 カイロン コーポレイション 非経口初回抗原刺激後の粘膜追加免疫
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
WO2003059385A2 (en) * 2002-01-14 2003-07-24 Chiron Corporation Hiv vaccine and method of use
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery

Also Published As

Publication number Publication date
JP2010202672A (ja) 2010-09-16
CN1684707A (zh) 2005-10-19
RU2004136295A (ru) 2006-03-20
NZ536859A (en) 2007-11-30
US20110159030A1 (en) 2011-06-30
JP4662537B2 (ja) 2011-03-30
AU2003239744B2 (en) 2008-07-03
WO2003094960A3 (en) 2004-03-04
AU2003239744A1 (en) 2003-11-11
RU2378008C2 (ru) 2010-01-10
CA2485999C (en) 2015-02-17
CA2485999A1 (en) 2003-11-20
WO2003094960A2 (en) 2003-11-20
CN1816350B (zh) 2010-11-10
US20060147466A1 (en) 2006-07-06
CN1684707B (zh) 2012-09-05
EP1506007A2 (de) 2005-02-16
MXPA04011248A (es) 2005-02-17
BR0310042A (pt) 2005-04-05
JP2005526847A (ja) 2005-09-08
CN1816350A (zh) 2006-08-09
EP1506007B1 (de) 2011-06-22

Similar Documents

Publication Publication Date Title
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
NO20031646D0 (no) Ajuvantsammensetning omfattende et immunostimulatorisk oligonukleotid og entokol
CY1114179T1 (el) Ανοσοποιηση εναντι μηνιγγιτιδοκοκκου οροομαδας υ με χρηση πρωτεϊνων
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
DK2353608T3 (da) Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
MA29459B1 (fr) Vaccins
JP2005526847A5 (de)
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
NO20015074D0 (no) Nye sammensetninger
WO2003047619A3 (en) Adjuvanted antigenic meningococcal compositions
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
BRPI0413509A (pt) uso de antibióticos de quinolona
DE60333027D1 (de) Antigene zusammensetzungen zur immunisierung nichtmenschlicher säuger gegen streptococcus equi
SG147465A1 (en) Vaccine
JP2005519123A5 (de)
WO2004083390A3 (en) Virulent systemic feline calicivirus
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
Dougan A single-dose, live oral typhoid vaccine: an achievable goal?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties